CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to REGN

aflibercept injection (VEGF Trap-Eye, BAY86-5321)

Phase 3
Regeneron Pharmaceuticals, Inc. (REGN)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Macular Degeneration

View Full Landscape
Drug Information

Target Indication

Macular Degeneration

Clinical Trial

NCT00320788

Last updated: 1/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.